CSX vs RCUS · P/E 19, rev $14.09B vs rev $258.0M
CSX Corporation (CSX) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
CSX Corporation (CSX) is a railroads company listed on US.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported CSX revenue for 2025-12-31 was $14.09B. Net income was $2.89B. Revenue was down 3.1% from 2024-12-31 to 2025-12-31. CSX currently screens at market cap $61.18B and trailing P/E 19.4.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
CSX currently screens at market cap $61.18B and trailing P/E 19.4. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the CSX and RCUS stock pages for the full models.
Not investment advice.